Related Experiment Videos
[Targeted therapies in thoracic oncology]
E Quoix1, M Beau-Faller, J-Y Douillard
1Service de Pneumologie Lyautey, Hôpitaux Universitaires, Strasbourg, France. elisabeth.quiox@chru-strasbourg.fr
Revue Des Maladies Respiratoires
|August 5, 2004
Summary
Biological targeted therapies offer new anticancer strategies complementing traditional treatments. Epidermal Growth Factor Receptor (EGFR) inhibitors are most advanced, showing sustained responses with some toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Carcinogenesis involves cellular physiology alterations, driving development of novel anticancer agents.
- Targeted therapies are emerging as crucial complements to traditional cancer treatments like surgery, radiotherapy, and chemotherapy.
Purpose:
- To review the landscape of biological targeted therapies in thoracic oncology.
- To highlight the role of growth factor receptor inhibitors, particularly EGFR inhibitors, in cancer treatment.
Summary:
- Biological targeted therapies interfere with cancer cell signaling pathways.
- Epidermal Growth Factor Receptor (EGFR) inhibitors, including monoclonal antibodies and tyrosine-kinase inhibitors, are the most clinically advanced targeted agents.
- While EGFR inhibitors demonstrate clinical activity and potential for sustained responses, they are associated with specific toxicities.
Impact:
- These targeted therapies represent a significant advancement in personalized cancer medicine.
- Further research into targeted agents like farnesyl transferase inhibitors and angiogenesis inhibitors holds promise for future cancer treatment strategies.